CUR treatment leads to a decrease in the accretion of S-phase kinase-associated protein 2 (S-phase Skp2) and enhances p27 protein accumulation in the pancreatic cancer cell, resulting in a significant amelioration of diabetic nephropathy [131,132]. The gene discussed is SKP2; the disease is diabetic kidney disease.